Diane D Liu
Overview
Explore the profile of Diane D Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
2933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie X, Chauhan G, Edupuganti R, Kogawa T, Park J, Tacam M, et al.
Cancer Res Commun
. 2024 Jan;
4(1):236.
PMID: 38282551
No abstract available.
2.
Mustafayev F, Liu D, Gutierrez A, Lewis J, Ibrahim N, Valero V, et al.
Eur J Breast Health
. 2023 Oct;
19(4):267-273.
PMID: 37795002
Objective: Risk-reducing therapy with selective estrogen receptor (ER) modulators and aromatase inhibitors reduce breast cancer risk. However, the effects are limited to ER-positive breast cancer. Therefore, new agents with improved...
3.
Xie X, Chauhan G, Edupuganti R, Kogawa T, Park J, Tacam M, et al.
Cancer Res Commun
. 2023 Jun;
3(6):1078-1092.
PMID: 37377604
Significance: These findings indicate that MELK is a driver of aggressiveness and metastasis in TNBC.
4.
OShea A, Clifton G, Qiao N, Heckman-Stoddard B, Wojtowicz M, Dimond E, et al.
Cancer Prev Res (Phila)
. 2023 Jun;
16(6):333-341.
PMID: 37259799
Prevention Relevance: This trial showed that vaccination of patients with HLA-A2-positive DCIS with NeuVax in the preoperative setting can induce a sustained antigen-specific T-cell response. This provides proof of principle...
5.
Thomas P, Patel A, Lee J, Liu D, Hernandez M, Muzzio M, et al.
Cancer Prev Res (Phila)
. 2022 Oct;
16(1):47-55.
PMID: 36228112
Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. This phase I study evaluates topical bexarotene, as a potential...
6.
Yennurajalingam S, Valero V, Lu Z, Liu D, Busaidy N, Reuben J, et al.
J Natl Compr Canc Netw
. 2021 Dec;
20(3):235-243.
PMID: 34965510
Background: Despite the high frequency of cancer-related fatigue (CRF) and its debilitating effects on the quality of life of patients with advanced cancer, there are limited treatment options available. Treatments...
7.
Kai M, Marx A, Liu D, Shen Y, Gao H, Reuben J, et al.
Sci Rep
. 2021 Nov;
11(1):22242.
PMID: 34782633
Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional...
8.
Al Feghali K, Randall J, Liu D, Wefel J, Brown P, Grosshans D, et al.
Neurooncol Adv
. 2021 Aug;
3(1):vdab073.
PMID: 34337411
Background: This secondary image analysis of a randomized trial of proton radiotherapy (PT) versus photon intensity-modulated radiotherapy (IMRT) compares tumor progression based on clinical radiological assessment versus Response Assessment in...
9.
Tennison J, Ng A, Rianon N, Liu D, Bruera E
Oncologist
. 2021 Jun;
26(10):887-896.
PMID: 34080755
Background: Patients with cancer have been noted to have inadequate continuity of care after discharge from hospital. We sought to assess patient-reported continuity of care and functional safety concerns after...
10.
Delgado-Guay M, Palma A, Duarte E, Grez M, Tupper L, Liu D, et al.
J Palliat Med
. 2021 Apr;
24(11):1606-1615.
PMID: 33844951
The purpose of this multicenter study was to characterize the association between spirituality, religiosity, spiritual pain, symptom distress, coping, and quality of life (QOL) among Latin American advanced cancer patients....